Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a fu
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved
